Bioantibody has completed its first round of financing totaling nearly 100 million yuan. This financing was led by Fang Fund and followed by New Industry Investment, Guoqian Venture Investment, Bondshine Capital. Phoenix Tree Capital acted as the exclusive financial advisor.

The US Food and Drug Administration said on Tuesday it has granted Emergency Use Authorization for DiaCarta's monkeypox PCR test.

Jiangsu Huadong Medical Device Industrial and Getein Biotech have signed an agreement to jointly manufacture and sell antigen test kits for Covid-19 and other in vitro diagnostics (IVD) products.

On January 9, Fosun Foundation, together with Fosun Pharma and Henan Genuine Biotech Co., Ltd., announced that they will donate 100 million yuan worth of oral drug Azvudine to rural areas in China.

Becton, Dickinson and Company (BD) and CerTest Biotec have announced that their molecular assay for detecting the Mpox virus has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA).

QIAGEN today announced it has completed the acquisition of Verogen, a leader in the use of next-generation sequencing (NGS) technologies to drive the future of human identification (HID) and forensic investigation.

On January 5, 2023, Guangzhou Darui Biotechnology Co., Ltd., the subsidiary of Daan Gene Co., Ltd., received China National Medical Products Administration (NMPA) class III medical device approval for its “Twenty Genetic Deafness Genes Mutation Detection Kit (Time of Flight Mass Spectrometry)”.

Genomic and diagnostic testing company Prenetics Global said Tuesday that the US Food and Drug Administration has cleared ACTOnco, a comprehensive genomic profiling test for solid tumors.

Foundation Medicine and Karyopharm Therapeutics said Tuesday they are collaborating on a companion diagnostic for Karyopharm's experimental drug Xpovio (selinexor), which is in development as a maintenance therapy for patients with advanced or recurrent TP53 wild-type endometrial cancer.

January 10, Suzhou Nanomicro Technology Co., Ltd. issued a voluntary disclosure announcement for its 2022 annual results forecast.

Foundation Medicine, Inc., a pioneer in molecular profiling for cancer, and Natera, Inc., a global leader in cell-free DNA testing, today launched an early access program for clinical use of FoundationOne®Tracker, a personalized circulating tumor DNA (ctDNA) monitoring assay.

Being committed to continued advances in improving human health, SCHOTT has opened a new facility in Phoenix, Arizona, to expand the development and manufacturing of diagnostics and life science consumables.

Recently, Thalys Medical Technology was strongly recommended by MedTech Outlook and won the title of "Top Ten In Vitro Diagnostic Solution Providers in the Asia-Pacific Region in 2022".

TÜV SÜD said recently that it has certified a companion diagnostic manufactured by Roche under the EU's new In Vitro Diagnostic Regulation, adding it is the first such certification for a CDx.

Agilent Technologies Inc. announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing (NGS) approaches to study cancer.

Nanjing HumaDx Tech Co., Ltd. announced the completion of a Series A1 worth tens of millions of RMB, which was exclusively invested by Yuanbio Venture Capital, a well-known investment institution in the field of in vitro diagnostics.

QIAGEN announced an exclusive strategic partnership with California-based population genomics leader Helix to advance companion diagnostics for hereditary diseases.

Precision BioLogic said Thursday it secured US Food and Drug Administration 510(k) premarket clearance for its Cryocheck Chromogenic Factor IX test for managing hemophilia B.

Recently, an GDF-15 Chemiluminescence Immunoassay kit of Maccura Biotechnology Co., Ltd. obtained the medical certificate. This kit is the first certified Chemiluminescence Immunoassay kit for growth differentiation factor 15 in China.

General Electric completed the spinoff of its healthcare division on Wednesday morning as GE HealthCare began trading on the Nasdaq exchange under the ticker “GEHC” at $56 per share.